Sugi Predict

Sugi Predict / Compounds / SCHEMBL2483448

SCHEMBL2483448

SCHEMBL2483448

CCCN1CCN(c2cc(Nc3ccc4c(c3)OCCO4)c3c4c(onc24)-c2ccccc2C3=O)CC1

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ EHMT2 Q96KQ7 14/20 0.61
▸ PLAU P00749 1/20 0.54
▸ MAPT P10636 3/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ APP P05067 1/20 0.53
▸ THRB P10828 1/20 0.53
▸ TSHR P16473 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ SNCA P37840 1/20 0.53
▸ BRCA1 P38398 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ NTRK1 P04629 1/20 0.52
▸ PLAUR Q03405 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2483882 0.85 EHMT2 (0.71) EHMT2PLAUMAPTMEN1APP
SCHEMBL15958451 0.84 EHMT2 (0.68) EHMT2PLAUMAPTMEN1APP
SCHEMBL13284991 0.84 EHMT2 (0.67) EHMT2PLAUMAPTMEN1APP
SCHEMBL2628848 0.84 NTRK1 (0.74) EHMT2PLAUMAPTTHRBNTRK1
SCHEMBL2628847 0.79 NTRK1 (0.74) EHMT2PLAUMAPTTHRBNTRK1
SCHEMBL13284988 0.78 EHMT2 (0.68) EHMT2MAPTMEN1APPTHRB
SCHEMBL17874500 0.75 PLAU (0.81) EHMT2PLAUMAPTNTRK1PLAUR
SCHEMBL13285003 0.75 EHMT2 (0.73) EHMT2PLAUMAPTMEN1APP
SCHEMBL15939758 0.73 EHMT2 (0.55) EHMT2MAPTMEN1APPTHRB
SCHEMBL19680034 0.73 PLAUR (0.70) EHMT2PLAUMAPTMEN1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301133-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2011-12-08 — — US claimed
US-10421763-B2 Compositions of protein receptor tyrosine kinase inhibitors PURDUE PHARMA L.P. (US) 2019-09-24 — — US disclosed
US-10421763-B2 Compositions of protein receptor tyrosine kinase inhibitors PURDUE PHARMA L.P. (US) 2019-09-24 — — US disclosed
US-20180086777-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS PURDUE PHARMA L.P. (US) 2018-03-29 — — US disclosed
US-20180086777-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS PURDUE PHARMA L.P. (US) 2018-03-29 — — US disclosed
US-9738659-B2 Compositions of protein receptor tyrosine kinase inhibitors PURDUE PHARMA L.P. (US) 2017-08-22 — — US disclosed
US-9738659-B2 Compositions of protein receptor tyrosine kinase inhibitors PURDUE PHARMA L.P. (US) 2017-08-22 — — US disclosed
US-9738659-B2 Compositions of protein receptor tyrosine kinase inhibitors PURDUE PHARMA L.P. (US) 2017-08-22 — — US disclosed
US-20150218188-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2015-08-06 — — US disclosed
US-20150218188-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2015-08-06 — — US disclosed
US-8809530-B1 Compositions of protein receptor tyrosine kinase inhibitors VM PHARMA LLC (US) 2014-08-19 — — US disclosed
US-20140228331-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS PURDUE PHARMA L.P. 2014-08-14 — — US disclosed
US-20140228331-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS PURDUE PHARMA L.P. 2014-08-14 — — US disclosed
US-20140228331-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS PURDUE PHARMA L.P. 2014-08-14 — — US disclosed
US-20110301133-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2011-12-08 — — US disclosed
US-20110301133-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2011-12-08 — — US disclosed
US-20110301133-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2011-12-08 — — US disclosed
EP-2376495-A2 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM Pharma LLC (US) 2011-10-19 — — EP disclosed
WO-2010077680-A2 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM DISCOVERY INC. (US) 2010-07-08 — — WO disclosed
WO-2010077680-A2 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM DISCOVERY INC. (US) 2010-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218188-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS NGFR, NGF, GRB2 EHMT2 4599/4885PLAU 2527/4885MAPT 576/4885
US-10421763-B2 Compositions of protein receptor tyrosine kinase inhibitors NGFR, NGF, GRB2 EHMT2 4599/4885PLAU 2527/4885MAPT 576/4885
US-20140228331-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS NGFR, NGF, GRB2 EHMT2 4599/4885PLAU 2527/4885MAPT 576/4885
US-20180086777-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS NGFR, NGF, GRB2 EHMT2 4560/4885PLAU 2526/4885MAPT 536/4885
US-20110301133-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS NGFR, NGF, GRB2 EHMT2 4599/4885PLAU 2527/4885MAPT 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.